Background and aim: Persistent hyperparathyroidism after renal transplantation, termed tertiary hyperparathyroidism, is not uncommon. We aimed to identify the prevalence of persistent hyperparathyroidism after successful kidney transplantation and to study the associated risk factors.
Methods: This is a cross-sectional study including 63 patients who underwent renal transplantation for the first time &for at least a year. Data was collected about demographic characteristics, duration of chronic kidney disease& dialysis therapy, history of hypertension, diabetes mellitus, coronary heart disease and use of medications including vitamin D. Levels of serum calcium and phosphate and renal function test were recorded prior and post- transplantation. Serum parathyroid hormone was tested only post- transplantation. The association of those variable with hyperparathyroidism was studied by Pearson’s correlation. P≤0.05 was considered statistically significant.
Results: Hyperparathyroidism was found in 53 (84.10%) patients, there was a strong positive correlation of parathyroid hormone level and serum levels of calcium and phosphate with (p-value<0.001). While the correlation was negative of parathyroid hormone level and estimated glomerular filtration rate after transplantation. None of the variables apart from hypertension was strongly associated as a risk factor before transplantation for persistant hyperparathyroidism.
Conclusions: In this single center study; more than 80% of post-transplant patients with normal transplant function, have elevated levels of parathyroid hormone more than one year after transplantation. This may have a major impact on clinical treatment guidelines. However, no association was observed between pre-transplant age, duration of transplant, duration on dialysis as risk factors for persistent hyperparathyroidism.
Cunningham J, Locatelli F, and Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol, vol 6,no.4,pp. 913-21, 2011.
Copley JB, and Wuthrich RP. Therapeutic management of post-kidney transplant hyperparathyroidism. Clin Transplant, vol. 25, no. 1, pp. 24-39, 2011.
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. Vol. 42, S1-201, 2003.
Bleskestad IH, Bergrem H, Leivestad T, and Gøransson LG. Intact parathyroid hormone levels in renal transplant patients with normal transplant function. Clin Transplant. Vol. 25, no. 5. pp. E566-70, 2011.
Muirhead N, Zaltman JS, Gill JS, Churchill DN, Poulin-Costello M, Mann V, et al. Hypercalcemia in renal transplant patients: prevalence and management in Canadian transplant practice. Clin Transplant. 2014;28(2):161–5.
Tillmann FP, Wächtler C, Hansen A, Rump LC,Quack I. Vitamin D and cinacalcet administration pre-transplantation predict hypercalcaemic hyperparathyroidism post-transplantation: a case-control study of 355 deceased-donor renal transplant recipients over 3 years. Transplant Res. 2014; 3(1):21.
Sprague SM, Belozeroff V, Danese MD, Martin LP, Olgaard K. Abnormal bone and mineral metabolism in kidney transplant patients--a review. Am J Nephrol. 2008; 28(2):246-53.
Borchhardt K, Sulzbacher I, Benesch T, Födinger M, Sunder-Plassmann G, Haas M. Low-turnover bone disease in hypercalcemic hyperparathyroidism after kidney transplantation. Am J Transplant. 2007; 7(11):2515-21.
Sirilak S, Chatsrisak K, Ingsathit A, Kantachuvesiri S, Sumethkul V, Stitchantrakul W, et al. Renal phosphate loss in long-term kidney transplantation. Clin J Am Soc Nephrol. 2012; 7(2):323-31.
Wesseling-Perry K, Tsai EW, Ettenger RB, Jüppner H, Salusky IB. Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: a role for FGF-23? Nephrol Dial Transplant 2011; 26(11):3779-84.
Delos Santos R, Rossi A, Coyne D, Maw TT. Management of Post-transplant Hyperparathyroidism and Bone Disease. Drugs 2019; 79(5): 501–513.
Baia LC, Humalda JK, VervloetMG,Navis G, Bakker SJ, de Borst MH, et al. Fibroblast growth factor 23 and cardiovascular mortality after kidney transplantation. Clin J Am Soc Nephrol. 2013; 8(11):1968-78.
Komaba H, Taniguchi M, Wada A, Iseki K, Tsubakihara Y, Fukagawa M. Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int. 2015; 88(2):350-9.
Roodnat JI, van Gurp EA, Mulder PG,van Gelder T, de Rijke YB, de Herder WW, et al. High pretransplant parathyroid hormone levels increase the risk for graft failure after renal transplantation. Transplantation. 2006; 82(3):362-7.
Hernández D, Rufino M, BartolomeiS,González-Rinne A, Lorenzo V, et al. Clinical impact of preexisting vascular calcifications on mortality after renal transplantation. Kidney Int. 2005; ;67(5):2015-20.
Wolf M, Molnar MZ, Amaral AP,Czira ME, Rudas A, Ujszaszi A, et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol. 2011; 22(5):956-66.
Kandil E, Florman S, Alabbas H, Abdullah O, McGee J, Noureldine S, et al. Exploring the effect of parathyroidectomy for tertiary hyperparathyroidism after kidney transplantation. Am J Med Sci. 2010; 339(5):420-24.
Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, et al. Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what’s changed and why it matters. Kidney Int. 2017;92(1):26–36. doi: 10.1016/j.kint.2017.04.006.
Stuart HR, Ian DP, Mark WJ, Richard PH. Davidson's principles and practice of medicine. Edinburgh: Elsevier; 2018. 386 p.
Jameson JL, Faucei AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J. Harrison’s principles of internal medicine. New York: McGraw Hill Medical Publishing division; 2018. 2925-2933 p.
Vinay K, Abbas AK, Jon CA. Robbins Basic Pathology. Canada: Elsevier; 2013. 738p.
Braunwald E, Faucei AS, Kasper DL, Hauser SL, Longo DL, Larry JJ. Harrison’s principles of internal medicine. New York: McGraw Hill Medical Publishing division; 2018. 2047 p.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010; 33(Suppl. 1): S62–S69.
2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of Patients with Stable Ischemic Heart Disease. Journal of the American College of Cardiology. 2014;64(18 1929-1949).
Al-Moasseb Z, Aitken E. Natural History of Serum Calcium and Parathyroid Hormone Following Renal Transplantation. Transplantation Proceedings 2016. 48(10): 3285-91.
Triponez F, Dosseh D, Hazzan M,Noel C, Vanhille P, Fleury D, et al. Results of systematic subtotal parathyroidectomy with thymectomy for tertiary hyperparathyroidism after renal transplantation. Ann Chir. 2006;131(3):203-10.
Amin TP, Coates T, Barbara J, Hakendorf P, Karim N. Prevalence of Hypercalcaemia in a Renal Transplant Population:A Single Centre Study. International Journal of Nephrology; 2016, 2016(11):1-5.
Myles W, Matthew RW, Nelson K, Roslyn BM, Jon VV, Hongjie D, et al. A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation. Transplantation 2016, 100(1):184-193.
Yamamoto T, Tominaga Y, Okada M, Hiramitsu T, Tsujita M, Goto N, et al. Characteristics of Persistent Hyperparathyroidism After Renal Transplantation. World J Surg. 2016 Mar;40(3):600-6.
Tomida K, Hamano T, Ichimaru N, Fujii N, Matsui I, Nonomura N, et al. Dialysis vintage and parathyroid hormone level, not fibroblast growth factor-23, determines chronic-phase phosphate wasting after renal transplantation. Bone. 2012;51(4):729-36.
Jahromi AH, Roozbeh J, Raiss-Jalali JA, Dabaghmanesh A, Jalaeian H, Bahador A, et al. Risk factors of post renal transplant hyperparathyroidism. Saudi Journal Of Kidney Diseases And Tranplantation 2009; 20 (4): 573-576.
This work is licensed under a Creative Commons Attribution 4.0 International License.